Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | CNR2 | P34972 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554247 | 1.00 | LMNA (1.00) | LMNACHRM1TP53CNR2 | |
| SCHEMBL3234154 | 0.94 | LMNA (0.89) | LMNACHRM1TP53CNR2 | |
| SCHEMBL3228550 | 0.92 | LMNA (0.84) | LMNACHRM1TP53CNR2 | |
| SCHEMBL2487513 | 0.92 | LMNA (0.84) | LMNACHRM1TP53CNR2 | |
| SCHEMBL16341623 | 0.90 | LMNA (0.82) | LMNACHRM1TP53CNR2 | |
| SCHEMBL1549051 | 0.90 | LMNA (0.81) | LMNACHRM1TP53CNR2 | |
| SCHEMBL1606606 | 0.89 | LMNA (0.80) | LMNACHRM1CNR2 | |
| SCHEMBL16691692 | 0.88 | LMNA (0.79) | LMNACHRM1TP53CNR2 | |
| SCHEMBL29696585 | 0.88 | LMNA (0.79) | LMNACHRM1TP53CNR2 | |
| SCHEMBL18589532 | 0.88 | LMNA (0.78) | LMNACHRM1TP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573902-B2 | Process for the preparation of Ivacaftor and its intermediates | LAURUS LABS PRIVATE LTD. (IN) | 2017-02-21 | — | — | US | claimed |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | claimed |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | disclosed |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | disclosed |
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | LAURUS LABS LIMITED (IN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | LAURUS LABS LIMITED (IN) | 2020-12-31 | — | — | US | disclosed |
| EP-3344249-B1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | LAURUS LABS LTD (IN) | 2020-10-28 | — | — | EP | disclosed |
| US-10815202-B2 | Process for the preparation of ivacaftor | LAURUS LABS LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-10815202-B2 | Process for the preparation of ivacaftor | LAURUS LABS LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2019-11-14 | — | — | US | disclosed |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2019-11-14 | — | — | US | disclosed |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2014125506-A2 | A PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS PRIVATE LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014125506-A2 | A PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS PRIVATE LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5362734-A | Certain benzo-quinolizine compounds and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | disclosed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | disclosed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | ACVR1, SLC10A2, CYP4A11 | LMNA 1764/4885CHRM1 3411/4885TP53 4784/4885 |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | F5, CYP4A11, ACVR1 | LMNA 499/4885CHRM1 3297/4885TP53 4863/4885 |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | ACVR1, SLC10A2, CYP4X1 | LMNA 903/4885CHRM1 3270/4885TP53 4815/4885 |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | SLC10A2, SLC26A4, SLC10A1 | LMNA 1823/4885CHRM1 3052/4885TP53 4752/4885 |
| US-10815202-B2 | Process for the preparation of ivacaftor | F5, CYP4A11, ACVR1 | LMNA 499/4885CHRM1 3297/4885TP53 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.